Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Eupraxia Pharmaceuticals Q2 EPS $(0.26) Misses $(0.19) Estimate

Author: Benzinga Newsdesk | August 12, 2025 05:03pm
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.19) by 36.84 percent. This is a 52.94 percent decrease over losses of $(0.17) per share from the same period last year.

Posted In: EPRX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist